Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer

Frontiers in Immunology

Volumn 8, Issue , 2017, Pages

  Muraro, Elena ^a   Furlan, Carlo ^a   Avanzo, Michele ^a   Martorelli, Debora ^a   Comaro, Elisa ^a   Rizzo, Aurora ^a   Fae', Damiana A ^a   Berretta, Massimiliano ^a   Militello, Loredana ^a   Del Conte, Alessandro ^b   Spazzapan, Simon ^a   Dolcetti, Riccardo ^a,c   Trovo', Marco ^d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Pordenone General Hospital   (Italy)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine   (Italy)

Author keywords

Antitumor T cell responses; Immunomodulation; Oligometastatic breast cancer; Radiotherapy immunogenicity; Stereotactic body radiotherapy

Indexed keywords

ALBUMIN; CXCL16 CHEMOKINE; ESTROGEN RECEPTOR; FAS ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; PROGESTERONE RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GAMMA RADIATION; GENOTYPE; HUMAN; IMMUNOMODULATION; IMMUNOPHENOTYPING; LIVER METASTASIS; METASTATIC BREAST CANCER; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; RNA EXTRACTION; STEREOTACTIC BODY RADIATION THERAPY; TH17 CELL; TUMOR MICROENVIRONMENT;

EID: 85032808952     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01476     Document Type: Article

References (58)

1. Kobayashi H, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer (2012) 19:218-37. doi:10.1007/s12282-012-0347-0
2. Di Lascio S, Pagani O. Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care (Basel) (2014) 9:7-14. doi:10.1159/000358750
3. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol (1995) 13:8-10. doi:10.1200/JCO.1995.13.1.8
4. Ricardi U, Badellino S, Filippi AR. Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res (2016) 57(Suppl 1):i58-68. doi:10.1093/jrr/rrw006
5. Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G, Denning MD. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys (2010) 77:1146-50. doi:10.1016/j.ijrobp.2009.06.017
6. Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, et al. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast (2016) 26:11-7. doi:10.1016/j.breast.2015.12.002
7. Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett (2015) 356:82-90. doi:10.1016/j.canlet.2013.09.018
8. de la Cruz-Merino L, Illescas-Vacas A, Grueso-Lopez A, Barco-Sanchez A, Miguez-Sanchez C; Cancer Immunotherapies Spanish Group (GETICA). Radiation for awakening the dormant immune system, a promising challenge to be explored. Front Immunol (2014) 5:102. doi:10.3389/fimmu.2014. 00102
9. Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol (2011) 2011:439752. doi:10.1155/2011/ 439752
10. Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treat Rev (2005) 31:159-72. doi:10.1016/j.ctrv.2005.03.004
11. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget (2014) 5:403-16. doi:10.18632/oncotarget.1719
12. Penn I. Tumors of the immunocompromised patient. Annu Rev Med (1988) 39:63-73. doi:10.1146/annurev.me.39.020188.000431
13. Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res (2014) 16:204. doi:10.1186/bcr3620
14. Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G. New strategies in breast cancer: immunotherapy. Clin Cancer Res (2016) 22:2105-10. doi:10.1158/1078-0432.CCR-15-1315
15. Miolo G, Muraro E, Martorelli D, Lombardi D, Scalone S, Spazzapan S, et al. Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer (2014) 14:954. doi:10.1186/1471-2407-14-954
16. Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, et al. Improved natural killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. J Transl Med (2015) 13:204. doi:10.1186/s12967-015-0567-0
17. Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol (2015) 26:2429-36. doi:10.1093/annonc/mdv395
18. Tonks S, Marsh SG, Bunce M, Bodmer JG. Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop. Tissue Antigens (1999) 53:175-83. doi:10.1034/j. 1399-0039.1999.530208.x
19. Entz P, Toliat MR, Hampe J, Valentonyte R, Jenisch S, Nurnberg P, et al. New strategies for efficient typing of HLA class-II loci DQB1 and DRB1 by using pyrosequencing. Tissue Antigens (2005) 65:67-80. doi:10.1111/j. 1399-0039.2005.00345.x
20. Laske K, Shebzukhov YV, Grosse-Hovest L, Kuprash DV, Khlgatian SV, Koroleva EP, et al. Alternative variants of human HYDIN are novel cancerassociated antigens recognized by adaptive immunity. Cancer Immunol Res (2013) 1:190-200. doi:10.1158/2326-6066.CIR-13-0079
21. Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, et al. Identification of subtypes in human epidermal growth factor receptor 2 -positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol (2010) 28:1813-20. doi:10.1200/JCO.2009.22.8775
22. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med (2008) 6:25. doi:10.1186/1479-5876-6-25
23. Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol (2017) S0167-8140(17):32556-32552. doi:10.1016/j.radonc.2017.08.032
24. Heylmann D, Rodel F, Kindler T, Kaina B. Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells. Biochim Biophys Acta (2014) 1846:121-9. doi:10.1016/j.bbcan.2014.04.009
25. Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, et al. Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients. Radiother Oncol (2016) 118:176-80. doi:10.1016/j.radonc.2015.11.016
26. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 8:247-58. doi:10.1038/nri2274
27. Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, et al. gamma-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One (2011) 6:e28217. doi:10.1371/journal.pone.0028217
28. Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, et al. A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Cancer Res (2017) 23:5055-65. doi:10.1158/1078-0432.CCR-16-2946
29. Poleszczuk JT, Luddy KA, Prokopiou S, Robertson-Tessi M, Moros EG, Fishman M, et al. Abscopal benefits of localized radiotherapy depend on activated T-cell trafficking and distribution between metastatic lesions. Cancer Res (2016) 76:1009-18. doi:10.1158/0008-5472.CAN-15-1423
30. Burnette B, Weichselbaum RR. Radiation as an immune modulator. Semin Radiat Oncol (2013) 23:273-80. doi:10.1016/j.semradonc.2013.05.009
31. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res (2006) 66:4952-60. doi:10.1158/0008-5472.CAN-05-3918
32. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 285:727-9. doi:10.1126/science.285.5428.727
33. Kubo M, Morisaki T, Matsumoto K, Tasaki A, Yamanaka N, Nakashima H, et al. Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. Cancer Immunol Immunother (2005) 54:468-76. doi:10.1007/s00262-004-0617-6
34. Hamidullah K, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat (2012) 133:11-21. doi:10.1007/s10549-011-1855-x
35. Schaue D, Kachikwu EL, McBride WH. Cytokines in radiobiological responses: a review. Radiat Res (2012) 178:505-23. doi:10.1667/RR3031.1
36. Zuccari DA, Leonel C, Castro R, Gelaleti GB, Jardim BV, Moscheta MG, et al. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem (2012) 114:571-6. doi:10.1016/j.acthis.2011.10.007
37. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat (2007) 102:129-35. doi:10.1007/s10549-006-9328-3
38. Wirsdorfer F, Jendrossek V. The role of lymphocytes in radiotherapyinduced adverse late effects in the lung. Front Immunol (2016) 7:591. doi:10.3389/fimmu.2016.00591
39. Fujikawa K, Matsui Y, Miura K, Kobayashi T, Oka H, Fukuzawa S, et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol (2000) 164:673-5. doi:10.1016/S0022-5347(05)67278-3
40. Wang K, Vella AT. Regulatory T cells and cancer: a two-sided story. Immunol Invest (2016) 45:797-812. doi:10.1080/08820139.2016.1197242
41. Gough MJ, Young K, Crittenden M. The impact of the myeloid response to radiation therapy. Clin Dev Immunol (2013) 2013:281958. doi:10.1155/2013/ 281958
42. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Lekander M, Nilsson B, et al. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunol Immunother (2009) 58:111-20. doi:10.1007/s00262-008-0530-5
43. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 105:256-65. doi:10.1093/jnci/ djs629
44. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 7:31-40. doi:10.2174/ 156800907780006896
45. Derer A, Spiljar M, Baumler M, Hecht M, Fietkau R, Frey B, et al. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunol (2016) 7:610. doi:10.3389/fimmu.2016. 00610
46. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014) 5:1038-51. doi:10.18632/oncotarget.1637
47. Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol (2015) 25:28-33. doi:10.1016/j.semradonc.2014.07.004
48. Twyman-Saint VC, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 520:373-7. doi:10.1038/ nature14292
49. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 366:925-31. doi:10.1056/NEJMoa1112824
50. Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology (2015) 4:e1046028. doi:10.1080/2162402X.2015.1046028
51. Ribeiro GJ, Schmerling RA, Haddad CK, Racy DJ, Ferrigno R, Gil E, et al. Analysis of the abscopal effect with anti-PD1 therapy in patients with metastatic solid tumors. J Immunother (2016) 39:367-72. doi:10.1097/ CJI.0000000000000141
52. Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud V, et al. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. Melanoma Res (2017) 27:485-91. doi:10.1097/CMR. 0000000000000386
53. Demaria S, Formenti SC. Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? J Immunother Cancer (2016) 4:29. doi:10.1186/s40425-016-0133-1
54. Denkert C. The immunogenicity of breast cancer -molecular subtypes matter. Ann Oncol (2014) 25:1453-5. doi:10.1093/annonc/mdu235
55. Dewan MZ, Galloway AE, Kawashima N, DeWyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 15:5379-88. doi:10.1158/1078-0432.CCR-09-0265
56. Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, et al. TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 17:6754-65. doi:10.1158/1078-0432.CCR-11-0544
57. Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, et al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res (2015) 75:2232-42. doi:10.1158/0008-5472.CAN-14-3511
58. Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, Garcia-Martinez E, Rudqvist NP, et al. Barriers to radiation-induced in situ tumor vaccination. Front Immunol (2017) 8:229. doi:10.3389/fimmu.2017.00229